(Q34036872)

English

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (English)

1 reference

Europe PubMed Central

30 July 2017

steatohepatitis

0 references

fatty liver disease

0 references

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

object named as

Anne Tailleux

9

0 references

object named as

Bart Staels

1

0 references

author name string

Anne Rubenstrunk

2

1 reference

Europe PubMed Central

30 July 2017

Benoit Noel

3

1 reference

Europe PubMed Central

30 July 2017

Géraldine Rigou

4

1 reference

Europe PubMed Central

30 July 2017

Philippe Delataille

5

1 reference

Europe PubMed Central

30 July 2017

Lesley J Millatt

6

1 reference

Europe PubMed Central

30 July 2017

Morgane Baron

7

1 reference

Europe PubMed Central

30 July 2017

Anthony Lucas

8

1 reference

Europe PubMed Central

30 July 2017

Dean W Hum

10

1 reference

Europe PubMed Central

30 July 2017

Vlad Ratziu

11

1 reference

Europe PubMed Central

30 July 2017

Bertrand Cariou

12

1 reference

Europe PubMed Central

30 July 2017

Rémy Hanf

13

1 reference

Europe PubMed Central

30 July 2017

language of work or name

0 references

publication date

29 October 2013

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

58

1 reference

Europe PubMed Central

30 July 2017

6

1 reference

Europe PubMed Central

30 July 2017

1941-1952

1 reference

Europe PubMed Central

30 July 2017

Recent advances in nonalcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

NASH: a hidden and silent fibroser finally revealed?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment options for nonalcoholic fatty liver disease.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

PPARs: fatty acid sensors controlling metabolism

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Roles of PPARs in NAFLD: potential therapeutic targets

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Modulation of hepatic inflammatory risk markers of cardiovascular diseases by PPAR-alpha activators: clinical and experimental evidence

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome Proliferator-Activated Receptor α Protects against Obesity-Induced Hepatic Inflammation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

PPARdelta regulates glucose metabolism and insulin sensitivity

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Positive regulation of the peroxisomal beta-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptors and hepatic stellate cell activation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection from liver fibrosis by a peroxisome proliferator-activated receptor δ agonist

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

The PPARβ/δ activator GW501516 prevents the down-regulation of AMPK caused by a high-fat diet in liver and amplifies the PGC-1α-Lipin 1-PPARα pathway leading to increased fatty acid oxidation.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Peroxisome proliferator-activated receptor-beta signaling contributes to enhanced proliferation of hepatic stellate cells.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of intestinal peroxisome proliferator-activated receptor-α increases high-density lipoprotein production

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP.26461

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.26461

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34036872&oldid=1538906165"